5e5 of anti-PSMA CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human PSMA, His Tag (Cat. No. PSA-HP2Q3) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).
2e5 of PSMA-CAR-293 cells transfected with anti-PSMA-scFv were stained with 100 μL of 1 μg/mL of Biotinylated Human PSMA, His,Avitag (Cat. No. PSA-H5264) and negative control protein respectively, washed and then followed by PE anti-human IgG Fc antibody and analyzed with FACS (Routiney tested).
Immobilized Human PSMA, Fc Tag (Cat. No. PSA-H5264) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human PSMA Antibody, Human IgG1 with a linear range of 0.1-2 ng/mL (QC tested).
The purity of Rat PSMA, His Tag (Cat. No. PSA-R5245) is more than 90% and the molecular weight of this protein is around 170-208 kDa verified by SEC-MALS.
Measured by its ability to hydrolyze the substrate N-acetyl-L-Asp-L-Glu into N-acetyl-L-Asp and L-Glu. The L-Glu product is measured by fluorescence after its derivatization by ortho-phthaldialdehyde. The specific activity is >300 pmol/min/μg, as measured under the described conditions (QC tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Capromab pendetide | lndium-CYT-356; Indium-111-CYT-356; CYT-356; 111In CYT-356 | Approved | Eusa Pharma | ProstaScint | United States | Prostatic Neoplasms | Cytogen Corp | 1996-10-28 | Prostatic Neoplasms | Details |
| Lutetium (177Lu) vipivotide tetraxetan | PSMA-617-[177Lu]; Lutetium-177-PSMA-617; 177-Lu-PSMA-617; AAA-617; Lu-177- RLT | Approved | Radiomedix Inc | PLUVICTO | United States | Prostatic Neoplasms, Castration-Resistant | Advanced Accelerator Applications Usa Inc | 2022-03-23 | Carcinoma, Verrucous; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Carcinoma, Squamous Cell; Neoplasm Metastasis | Details |
| Piflufolastat F 18 | Approved | Johns Hopkins University | Pylarify | United States | Prostatic Neoplasms | Progenics Pharmaceuticals Inc | 2021-05-26 | Carcinoma, Renal Cell; Prostatic Neoplasms; Breast Neoplasms; Genital Neoplasms, Female; Neoplasm Metastasis; Adenocarcinoma | Details | |
| Ga-68 PSMA-11 | Ga-68-PSMA-11; Ga-68-PSMA; 68Ga-HBED-CC-PSMA11 | Approved | Radiomedix Inc | Gallium Ga 68 Psma-11, Illuccix, ILLUCCIX, Locametz | United States | Prostatic Neoplasms | Telix Pharmaceuticals Ltd, University Of California, San Francisco Foundation | 2020-12-01 | Solid tumours; Neoplasm Recurrence, Local; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Prostatic Neoplasms, Castration-Resistant; Urinary Bladder Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Neoplasm Metastasis; Carcinoma, Hepatocellular | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| CART-PSMA-TGFbRDN (University of Pennsylvania) | Phase 1 Clinical | University Of Pennsylvania | Prostatic Neoplasms | Details | |
| Autologous T-cell therapy (anti-PSMA-CD3), Roger Williams Medical Center | Phase 1 Clinical | Roger Williams Medical Center | Prostatic Neoplasms | Details | |
| 68Ga-PSMA-R2 (Advanced Accelerator Applications SA) | Clinical | Advanced Accelerator Applications Sa | Prostatic Neoplasms | Details | |
| TLX-592 | TLX-592 | Phase 2 Clinical | Telix Pharmaceuticals Ltd | Prostatic Neoplasms | Details |
| CONV-01-alpha + PSMA I&T | Phase 2 Clinical | Convergent Therapeutics Inc | Prostatic Neoplasms | Details | |
| ARX-517 | ARX-517 | Phase 1 Clinical | Ambrx Inc | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms | Details |
| 123-I-MIP-1095 | 123-I-MIP-1095 | Details | |||
| 123I-MIP-1072 | 123-I-MIP-1072 | Details | |||
| [131I]MIP-1095 | 1095; [131I]MIP-1095; [131I]MIP-1466 | Progenics Pharmaceuticals Inc | Details | ||
| JNJ-63898081 | JNJ-8081; JNJ-63898081 | Janssen Global Services Llc | Details | ||
| 177Lu-PSMA-R2 | 177Lu-PSMA-R2; 177Lu-PSMA-SR6; AAA-602 | Phase 2 Clinical | Advanced Accelerator Applications Sa | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms | Details |
| Pelgifatamab corixetan | BAY-2315497 | Phase 1 Clinical | Bayer AG | Prostatic Neoplasms | Details |
| LAVA-1207 | LAVA-1207 | Phase 2 Clinical | Vu University Medical Center | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms | Details |
| 177Lu-rhPSMA-10.1 | 177Lu-rhPSMA-10.1; (177Lu) rhPSMA-10.1 | Phase 2 Clinical | Blue Earth Therapeutics Ltd | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Urogenital Neoplasms; Prostatic Diseases | Details |
| Anti-PSMA CAR T-cell therapy (TNK Therapeutics) | Phase 1 Clinical | Sorrento Therapeutics Inc | Neoplasms | Details | |
| INO-5401 | INO-5401 | Phase 2 Clinical | Inovio Pharmaceuticals Inc | Glioblastoma; Carcinoma, Transitional Cell | Details |
| CBP-1018 | CBP-1018 | Phase 1 Clinical | Coherent Biopharma Suzhou Co Ltd | Solid tumours; Carcinoma, Renal Cell; Prostatic Neoplasms; Lung Neoplasms | Details |
| 68Ga-PSMA-IRDye | TLX591-Sx | Phase 2 Clinical | Telix Pharmaceuticals Ltd | Prostatic Neoplasms | Details |
| CCW-702 | CCW-702 | Phase 1 Clinical | The Scripps Research Institute Inc, Abbvie Inc | Prostatic Neoplasms | Details |
| 177Lu-EB-vipivotide tetraxetan | 177-Lu-EB-PSMA-617 | Phase 1 Clinical | National Institute For Biomedical Imaging And Bioengineering (Nibib), Peking Union Medical College Hospital | Carcinoma, Renal Cell; Prostatic Neoplasms, Castration-Resistant; Carcinoma, Adenoid Cystic; Prostatic Neoplasms | Details |
| PSMA-CART cell therapy (Shanghai Bioray Laboratory) | Phase 1 Clinical | Bioray Laboraytories Inc | Prostatic Neoplasms | Details | |
| P28z-CAR | P28z-CAR | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center, United States Department Of Defense | Prostatic Neoplasms | Details |
| 67Cu-SAR-bisPSMA (Clarity Pharmaceuticals) | Phase 2 Clinical | Clarity Pharmaceuticals Ltd | Prostatic Neoplasms, Castration-Resistant | Details | |
| 64Cu-SAR-bisPSMA (Clarity Pharmaceuticals) | Phase 2 Clinical | Clarity Pharmaceuticals Ltd | Prostatic Neoplasms, Castration-Resistant | Details | |
| GD2/PSMA Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | bi-4SCAR GD2/PSMA | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Solid tumours | Details |
| CD19/70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Lymphoma, B-Cell | Details | |
| PSMA/CD70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | bi-4SCAR PSMA/CD70 | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Neoplasms | Details |
| Gallium-68 PSMA-617 | 225 Ac-PSMA-617; 68Ga-PSMA-617; 68Ga-DKFZ-617; 68Ga-DKFZ-PSMA -617; 68Ga-DOTA-PSMA-DKFZ -617; Gallium-68-PSMA-617; PSMA-617-[68Ga] | Phase 3 Clinical | Peking Union Medical College Hospital | Prostatic Neoplasms | Details |
| 89Zr-DFO-huJ591 | Zr89-J591; 89Zr-DFO-J591; 89Zr-DFO-huJ591 | Phase 2 Clinical | Memorial Sloan Kettering Cancer Center | Prostatic Neoplasms | Details |
| 225 Actinium PSMA 617 (Novartis) | 225 Actinium PSMA-617; 225Ac-PSMA 617; AAA 817; 225Ac-PSMA-617 | Phase 1 Clinical | Novartis Pharma Ag, Endocyte Inc, Advanced Accelerator Applications Sa | Prostatic Neoplasms, Castration-Resistant | Details |
| CC-1 | CC-1 | Phase 2 Clinical | The University Of Tubingen, German Cancer Research Center (Dkfz) | Prostatic Neoplasms, Castration-Resistant; Carcinoma, Squamous Cell | Details |
| Lu-177-DGUL | PSMA-D GUL; Lu-177-DGUL; 177Lu-DOTA-GUL | Phase 2 Clinical | Cellbion Co Ltd | Neoplasms; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms | Details |
| 4SCAR-PSMA T cell therapy (Shenzhen Geno-Immune Medical Institute) | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Lymphoma, B-Cell; Neoplasms | Details | |
| JANX-007 | JANX-007; PSMA-TRACTr | Phase 1 Clinical | Janux Therapeutics Inc | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms | Details |
| HPN-424 | HPN-424 | Phase 2 Clinical | Harpoon Therapeutics | Prostatic Neoplasms | Details |
| Lutetium-177-PSMA-I&T | Phase 2 Clinical | Radboud University Nijmegen | Prostatic Neoplasms | Details | |
| Ga-68-NGUL | Phase 2 Clinical | Cellbion Co Ltd | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms | Details | |
| [177Lu]Ludotadipep | Phase 2 Clinical | Futurechem | Prostatic Neoplasms, Castration-Resistant | Details | |
| TNB-585 | AMG-340; TNB-585 | Phase 1 Clinical | Teneobio Inc, Amgen Inc | Prostatic Neoplasms, Castration-Resistant | Details |
| REGN-4336 | REGN-4336 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Prostatic Neoplasms, Castration-Resistant | Details |
| REGN-5678 | REGN-5678 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Prostatic Neoplasms, Castration-Resistant | Details |
| 18F-PSMA-1007 | 18F-PSMA-1007 | Phase 3 Clinical | Deutsches Krebsforschungszentrum | Prostatic Neoplasms | Details |
| Acapatamab | AMG-160 | Phase 2 Clinical | Amgen Inc | Prostatic Neoplasms, Castration-Resistant; Carcinoma, Non-Small-Cell Lung | Details |
| JNJ-80038114 | JNJ-80038114 | Phase 1 Clinical | Janssen Research & Development Llc | Prostatic Neoplasms | Details |
| Fluorine-18-CTT-1057 | CTT-1057; 18F-CTT1057; CTT-1057-18F; CTT-1057-F-18 | Phase 3 Clinical | Washington University, Cancer Targeted Technology Llc | Recurrence; Carcinoma, Renal Cell; Prostatic Neoplasms | Details |
| [177Lu]-CTT-1403 | CTT-1403; [177Lu]CTT1403; 177Lutetium CTT1403; [177Lu]CTT-1403 | Phase 1 Clinical | Cancer Targeted Technology Llc | Prostatic Neoplasms | Details |
| ATL-101 | MLN-591RL; ATL-101; huJ-591; MLN-591; J-591; Lu-177-J591; 177Lu-J591; 90Y-J591; muJ-591 | Phase 2 Clinical | Weill Medical College of Cornell University | Ovarian Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Glioma; Carcinoma, Non-Small-Cell Lung | Details |
| 177Lu-DOTA-rosopatamb | TLX591; 177Lu-DOTA-TLX591-CHO | Phase 3 Clinical | Telix Pharmaceuticals Ltd | Prostatic Neoplasms | Details |
| 177Lu-HTK03170 | 177Lu-HTK03170 | Phase 2 Clinical | British Columbia Cancer Agency | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms | Details |
| 68Ga-labeled NY108 | 68-Ga-labeled NY-108 | Phase 1 Clinical | Affiliated Hospital Of Jiangnan University | Prostatic Neoplasms | Details |
| [Lu177]-PNT-2002 | PNT-2002 | Phase 3 Clinical | Point Biopharma Inc | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms | Details |
| 225Ac-J591 | 225Ac-DOTA-J591; 225Ac-J591; CONV 01-α | Phase 2 Clinical | Cornell University | Prostatic Neoplasms | Details |
This web search service is supported by Google Inc.
A-Z
FLAG
Star Staining
ViruStop
Aneuro
ComboX
ActiveMax
GENPower
ClinMax 
Star Ribbon 
